Celltrion

Celltrion to unveil new drug development strategies at 2025 J.P. Morgan Healthcare Conference Korea Biomedical Review00:55JPMorgan Chase World Banking Pharma

Celltrion to unveil novel drug roadmap at JP Morgan Healthcare Conference The Korea Herald02:53JPMorgan Chase World Banking Pharma

Samsung, Celltrion to exhibit at J.P. Morgan Healthcare Conference Korea JoongAng Daily08:33JPMorgan Chase Consumer Electronics World Banking

Yungjin Pharm secures exclusive Korean distribution rights for Celltrion's Alzheimer’s patch Korea Biomedical Review02:50Alzheimer's Health

Celltrion receives FDA nod for phase 3 trial of Darzalex biosimilar Korea Biomedical Review05:18FDA Cancer Treatment Pharma

FDA approves Celltrion’s steqeyma (ustekinumab-stba) JD Supra17:05FDA

Celltrion's breast cancer drug Herzuma captures 74% market share in Japan Korea Biomedical Review01:43Cancer Treatment Breast Cancer Cancer

Eye on pharma: Korean drugmakers’ impact in Europe; new denosumab, eculizumab deals Center for Biosimilars12:10Pharma Top Tech Brands Samsung

Study confirms CT-P42 therapeutic equivalence to reference aflibercept in dme Center for Biosimilars19:20Pharma Diabetes Health

Spotlight on: Biosimilar litigations - January 2025 JD Supra23:35Patent Law Intellectual Property Sanofi

Latest News

Yesterday

Spotlight On: Biosimilar Litigations - January 2025 JD Supra23:35 13-Jan-25

Spotlight On: Rituxan® (rituximab) / Truxima® (rituximab-abbs) / Ruxience® (rituximab-pvvr) / Riabni™ (rituximab-arrx)… JD Supra22:34 13-Jan-25

In the last 7 days

Eye on Pharma: Korean Drugmakers’ Impact in Europe; New Denosumab, Eculizumab Deals Center for Biosimilars12:10 11-Jan-25

Celltrion to reveal four-year road map at J.P. Morgan Healthcare Conference Korea JoongAng Daily04:33 8-Jan-25

Celltrion to unveil novel drug roadmap at JP Morgan Healthcare Conference The Korea Herald02:53 8-Jan-25

Celltrion to unveil new drug development strategies at 2025 J.P. Morgan Healthcare Conference Korea Biomedical Review00:55 8-Jan-25

FDA Approves Celltrion’s STEQEYMA (ustekinumab-stba) JD Supra17:05 7-Jan-25

In the last month

Study Confirms CT-P42 Therapeutic Equivalence to Reference Aflibercept in DME Center for Biosimilars19:20 6-Jan-25

Samsung, Celltrion to exhibit at J.P. Morgan Healthcare Conference Korea JoongAng Daily08:33 6-Jan-25

Yungjin Pharm secures exclusive Korean distribution rights for Celltrion's Alzheimer’s patch Korea Biomedical Review02:50 6-Jan-25

Celltrion receives FDA nod for phase 3 trial of Darzalex biosimilar Korea Biomedical Review05:18 27-Dec-24

Celltrion's breast cancer drug Herzuma captures 74% market share in Japan Korea Biomedical Review01:43 26-Dec-24

Celltrion’s Actemra biosimilar wins approval in Korea Korea Biomedical Review01:58 23-Dec-24

Ustekinumab-stba Receives FDA Approval for Autoimmune Disorder and Inflammatory Bowel Disease Pharmacy Times17:07 18-Dec-24

FDA Approves Steqeyma: The Seventh Stelara Biosimilar Center for Biosimilars14:52 18-Dec-24

Celltrion's Crohn's treatment set for February U.S. release Korea JoongAng Daily09:12 18-Dec-24

Celltrion's Zymfentra wins nod for rheumatoid arthritis phase 3 trial in Europe Korea Biomedical Review05:58 18-Dec-24

U.S. FDA approves Celltrion's STEQEYMA® (ustekinumab-stba), a biosimilar to STELARA®… PR Newswire (Press Release)03:55 18-Dec-24

Spotlight On: Herceptin® (trastuzumab) / Ogivri® (trastuzumab-dkst) / Herzuma® (trastuzumab-pkrb) / Ontruzant®… JD Supra16:58 17-Dec-24

Celltrion launches CDMO subsidiary BioSolutions to achieve 3 trillion won sales goal Korea JoongAng Daily06:14 17-Dec-24

Celltrion to establish research center in India as part of global CDMO expansion Korea Biomedical Review04:58 17-Dec-24

Spotlight On: Biosimilar Litigations - December 2024 JD Supra19:23 16-Dec-24

Health Canada Approves First Omalizumab Biosimilar Center for Biosimilars18:21 16-Dec-24

Spotlight On: Rituxan® (rituximab) / Truxima® (rituximab-abbs) / Ruxience® (rituximab-pvvr) / Riabni™ (rituximab-arrx)… JD Supra17:31 16-Dec-24

Celltrion biosimilars recommended for EU approval Korea JoongAng Daily09:26 16-Dec-24

Celltrion wins positive CHMP opinions for 3 biosimilars in EU Korea Biomedical Review02:37 16-Dec-24

Celltrion Receives Positive CHMP Opinion for Three Biosimilars in the European Union Business Wire (Press Release)23:38 15-Dec-24

Stable Patient Satisfaction Found After Switching From the Humira or Biosimilar CT-P17 Center for Biosimilars12:15 14-Dec-24

view more headlines

13 Jan 23:35

About our Celltrion news

Latest news on Celltrion, a biopharmaceutical company headquartered in Incheon, South Korea.

Publication filters

Sorry, no headlines or news topics were found. Please try different keywords.